| Literature DB >> 8028669 |
K M Mohler1, P R Sleath, J N Fitzner, D P Cerretti, M Alderson, S S Kerwar, D S Torrance, C Otten-Evans, T Greenstreet, K Weerawarna.
Abstract
Tumour necrosis factor (tumour necrosis factor-alpha/cachectin) plays a critical role in certain physiological defensive responses but causes severe damage to the host organism when produced in excess. There are two forms of tumour necrosis factor, a type II membrane protein of relative molecular mass 26,000 (26K) and a soluble, 17K form generated from the cell-bound protein by proteolytic cleavage. The two forms of tumour necrosis factor and lymphotoxin-alpha (tumour necrosis factor-beta/lymphotoxin), a related protein, have similar but apparently not identical biological activities. A therapeutic agent which inhibited the release of tumour necrosis factor, but did not reduce the cell-associated activity or the level of lymphotoxin-alpha, might preserve the benefits of these cytokines while preventing tumour necrosis factor-induced damage. Here we describe a potent inhibitor of tumour necrosis factor processing and report that it protects mice from a lethal dose of endotoxin.Entities:
Mesh：
Substances：
Year: 1994 PMID： 8028669 DOI： 10.1038/370218a0
Source DB: PubMed Journal: Nature ISSN： 0028-0836 Impact factor: 49.962